Computerized Cognitive Bias Intervention for Intolerance of Uncertainty

June 27, 2016 updated by: Norman Schmidt, Florida State University
This investigation examines the efficacy of a brief, one-session computerized interpretation bias modification paradigm (CBM-I) in the reduction of intolerance of uncertainty. Intolerance of uncertainty is a risk factor for the development and maintenance of various forms of psychopathology.

Study Overview

Study Type

Interventional

Enrollment (Actual)

79

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Tallahassee, Florida, United States, 32306
        • Anxiety and Behavioral Health Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Elevated IU interpretation bias at pre-intervention.

Exclusion Criteria:

  • None.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active IU CBM-I
This paradigm was designed to train individuals to endorse benign interpretations of ambiguous information and reject negative/threatening interpretations of ambiguous information. Participant's baseline interpretation bias was measured at baseline. Participants then underwent two training phases in which their responses were either reinforced (i.e., they were told they were correct) or punished (i.e., they were told that they were incorrect). Interpretation bias was measured again at post-training.
Sham Comparator: Control CBM-I
This paradigm was identical to the active condition except that the word/sentence pairings used were not relevant to IU and/or anxiety.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in Intolerance of Uncertainty Scale-Short Form
Time Frame: Post-Intervention (directly following the intervention during their baseline appointment) to Month 1 Follow-up
Post-Intervention (directly following the intervention during their baseline appointment) to Month 1 Follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2014

Primary Completion (Actual)

May 1, 2016

Study Completion (Actual)

May 1, 2016

Study Registration Dates

First Submitted

June 21, 2016

First Submitted That Met QC Criteria

June 27, 2016

First Posted (Estimate)

June 29, 2016

Study Record Updates

Last Update Posted (Estimate)

June 29, 2016

Last Update Submitted That Met QC Criteria

June 27, 2016

Last Verified

June 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • Oglesby01

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intolerance of Uncertainty; Anxiety

Clinical Trials on Active IU CBM-I

3
Subscribe